By a News Reporter-Staff News Editor at Immunotherapy Weekly -- New research on Biological Therapy is the subject of a report. According to news reporting out of Taejon, South Korea, by NewsRx editors, research stated, "We report programmed nanoparticles (pNPs) that can tailor the immunotherapeutic function of primary bone marrow-derived dendritic cells (BMDCs) by ex vivo combined immunomodulation and track the in vivo migration of them after injection into body. Because DCs are the most effective antigen-presenting cells (APCs) that are able to present the antigens to T cells that contribute to tumor rejection, the maturation and monitoring of therapeutic DCs are essential for the efficient cancer immunotherapy."
Our news journalists obtained a quote from the research from Chungnam National University, "For combined immunomodulation of DCs, poly (lactic-co-glycolic acid) (PLGA) NPs containing both small interfering RNA (siRNA) for the knock-down of immune-suppressor gene (signal transducer and activator of transcription-3, STAT3) of DCs and an immune response modifier (imiquimod, R837) for the activation of DCs through the toll-like receptor 7 (TLR7) were developed. To deliver tumor antigen-specific information to DCs ex vivo and track the migration of DCs in vivo, another type of PLGA NPs containing tumor model antigen (ovalbumin, OVA) and near-infrared (NIR) fluorophores (indocyanine green, ICG) were also fabricated. These pNPs were taken up efficiently by DCs and various cytokines were expressed in matured DCs. DCs treated with pNPs also efficiently presented antigen-peptide to CD8 OVA 1.3 T cells through cross-presentation. Immunization of mice with these pNPs-treated DCs induced OVA-specific cytotoxic T lymphocytes (CTL) activity against the EG7-OVA tumor model and inhibited tumor growth efficiently. In addition, the migration of PLGA NPs-treated DCs to lymph nodes was monitored by NIR imaging technique."
According to the news editors, the research concluded: "These multifunctional pNPs represent a promising technology for the combined immunomodulation and antigen-specific tumor therapy."
For more information on this research see: Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells. Biomaterials, 2014;35(1):590-600. Biomaterials can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
Our news journalists report that additional information may be obtained by contacting M.B. Heo, Chungnam National University, Dept. of Analyt Sci & Technol, Taejon 305764, South Korea (see also Biological Therapy).
Keywords for this news article include: Asia, Taejon, Immunology, South Korea, Nanoparticle, Immunotherapy, Nanotechnology, Immunomodulation, Biological Therapy, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC